PHAR — Pharming Group N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1828316 ·
Last close
$10.08
Market Cap
$713.44M
52W High
$16.98
52W Low
$9.62
ADV30
8,283
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 90,213,000 | 75,668,000 | -111,000 | 1,638,000 | 467,984,000 | 158,281,000 | 197,494,000 |
| Mar 2026 | 72,447,000 | 65,803,000 | -5,288,000 | -5,213,000 | 489,365,000 | 52,379,000 | 220,405,000 |
| Dec 2025 | 106,500,000,000 | 85,400,000,000 | 2,000,000,000 | 5,300,000,000 | 499,963,000 | 145,305,000 | 222,861,000 |
| Sep 2025 | 97,287,000 | 90,216,000 | 15,751,000 | 7,548,000 | 473,785,000 | 132,370,000 | 209,141,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$54,708,000
Investing CF
$26,253,000
Financing CF
$1,495,000
CapEx
$-755,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-272,983,000
Inventory
$64,902,000
Receivables
$48,441,000
ST Investments
$33,796,000
EBIT TTM
$6,221,097,000
Pretax Income TTM
$4,808,049,000
Interest Exp TTM
$1,413,048,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$369,487,008
EBITDA
$42,282,000
Free Cash Flow
$59,018,124
Enterprise Value
$840,431,872
Total Cash
$170,175,008
Total Debt
$116,205,000
Shares Out
70,778,124
Trailing EPS
$0.14
Book Value
$3.61
ROE
5.0%
ROA
4.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,134,000 | 20,881,000 | 2,851,000 | 499,963,000 | 222,861,000 | — | 54,708,000 |
| Dec 2024 | 297,200,000 | -3,665,000 | -11,841,000 | 399,985,000 | 178,924,000 | — | -1,795,000 |
| Dec 2023 | 245,316,000 | -22,289,000 | -10,548,000 | 462,854,000 | 244,073,000 | — | -17,302,000 |
| Dec 2022 | 205,622,000 | 9,860,000 | 13,674,000 | 425,797,000 | 221,159,000 | — | 22,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $718.83M | $73.26 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $707.88M | $8.75 | — |
| MNPR | Monopar Therapeutics | $725.84M | $108.35 | — |
| ACRS | Aclaris Therapeutics, Inc. | $726.25M | $5.20 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $696.31M | $4.23 | — |
News headlines (Yahoo Finance, 1h cache)
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...
2026-07-30 19:04 · Yahoo
Pharming Group Q2 Earnings Call Highlights
2026-07-30 13:04 · Yahoo
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
2026-07-30 05:00 · Yahoo
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
2026-07-16 06:00 · Yahoo
Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case
2026-06-27 13:08 · Yahoo
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
2026-06-15 11:59 · Yahoo
High Growth Tech Stocks in Europe with Promising Potential
2026-06-05 05:38 · Yahoo
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
2026-06-04 05:00 · Yahoo
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
2026-06-02 06:00 · Yahoo
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
2026-05-28 14:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.